Jeffrey Carey, MD
Urology · Gahanna, OHNPI 1942241260
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Medtronic at 43.8% of the total. Reporting peaked in 2022 at $3,162 and has fallen 65.2% since, to $1,099 in 2025.
Across 222 payments — averaging $48.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Axonics, Inc.$3K
- Astellas Pharma US Inc$571
- Intuitive Surgical$485
- Sumitomo Pharma America, Inc.$380
- AbbVie$343
- plus $1K from 27 others
Across 31 payments — averaging $6386.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$184K
- Ironwood Pharmaceuticals, Inc$14K
What the payments were for
- Speaking & faculty fees$1,09510%
- Travel & lodging$3,51733%
- Food & beverage$5,39050%
- Education$5435%
- Gifts$1652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 88 | $4,695 |
| Axonics, Inc. | 26 | $2,766 |
| Astellas Pharma US Inc | 21 | $571 |
| Intuitive Surgical | 2 | $485 |
| Sumitomo Pharma America, Inc. | 20 | $380 |
| AbbVie(2 entities) | 16 | $343 |
| Boston Scientific | 5 | $280 |
| Caldera Medical, Inc | 1 | $212 |
| Bluewind Medical | 4 | $139 |
| Urovant Sciences Inc | 4 | $101 |
| Urogen Pharma, Inc. | 3 | $81 |
| Cardinal Health 200 LLC | 1 | $72 |
| Laborie Medical Technologies Corp. | 5 | $68 |
| Teleflex LLC | 2 | $64 |
| Coloplast | 2 | $57 |
| Merck | 2 | $52 |
| Myovant Sciences Inc. | 2 | $47 |
| AstraZeneca | 1 | $35 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Convatec Inc. | 1 | $27 |
| 180 Medical, Inc. | 1 | $25 |
| Antares Pharma, Inc. | 2 | $24 |
| Dendreon Pharmaceuticals LLC | 1 | $20 |
| Olympus America Inc. | 1 | $20 |
| Pfizer | 1 | $17 |
| Bayer | 1 | $16 |
| Applied Medical Technology Inc | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
| Procept Biorobotics Corporation | 1 | $13 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
| Cook Medical LLC | 1 | $13 |
| Amgen | 1 | $11 |
| RGH Enterprises LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,519
- Axonics$1,375
- Da Vinci Surgical System$485
- Bulkamid$396
- Desara$212
- BOTOX$129
- MYRBETRIQ$125
- Axonics r-SNM System$119
How this compares
$10,711 in reported general payments places this provider in the 80th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 75 | $70,477 |
| Methenamine Hippurate | 430 | $28,930 |
| GemtesaVibegron | 29 | $22,622 |
| Solifenacin Succinate | 379 | $22,426 |
| Estradiol | 169 | $13,825 |
| Trospium Chloride | 120 | $5,918 |
| Tamsulosin Hcl | 124 | $2,670 |
| Cephalexin | 315 | $2,554 |
| Trimethoprim | 32 | $2,326 |
| Potassium Citrate ErPotassium Citrate | 19 | $2,106 |
| Finasteride | 111 | $1,961 |
| Darifenacin ErDarifenacin Hydrobromide | 17 | $1,698 |
| Tolterodine Tartrate ErTolterodine Tartrate | 19 | $1,404 |
| Oxybutynin Chloride ErOxybutynin Chloride | 53 | $1,303 |
| YuvafemEstradiol | 13 | $1,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $571 | $70,47775 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $380 | $22,62229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 485 urology providers in Ohio.
Other urology in Gahanna
- Benjamin MartinGahanna$205K
- Lawrence GervasiMiddleburg Heights$1.1M
- Howard GoldmanCleveland$721K
- Ronney AbazaWorthington$374K
- Sriharan SivalingamCleveland$276K
- Sandip VasavadaCleveland$263K
- Jihad KaoukCleveland$234K
- Ruben OlivaresCleveland$184K
- Abhinav SidanaCincinnati$174K
- Raymond RackleyCleveland$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.